bags, tubing, filters, connectors, and mixers fabricated from polymers—presents potential sources of chemical compounds that can migrate into drug products. These compounds are classified as extractables when chemically extracted under aggressive laboratory conditions and as leachables when actually migrating into the product under normal process conditions.

Extractables typically originate from additives used in polymer manufacture such as plasticizers, antioxidants, stabilizers, and residual monomers. Leachables arise when these substances migrate into the biologic drug product during storage or production. Since such contaminating substances have the potential to affect product efficacy, safety, and stability, rigorous controls are mandatory.

Regulatory agencies recognize these risks and expect comprehensive controls and evaluations of extractables and leachables as part of drug product development, manufacturing, and stability testing programs under GMP frameworks. The FDA and EMA guidelines emphasize that manufacturers must establish robust leachable management programs ensuring patient safety and product integrity.

Effective leachables management in GMP biotechnology single-use systems requires a scientifically driven approach incorporating detailed characterization, risk assessments, toxicological evaluations, and stringent acceptance criteria matched with appropriate extraction testing methodologies.

Step 1: Material and Supplier Qualification for Single-Use Components

Begin the control program by thoroughly qualifying the materials used in single-use components and their suppliers. This foundational action ensures traceability, material compliance, and minimizes variability that can affect leachable profiles.

Supplier Evaluation

• Obtain detailed chemical composition data for polymers and additives from suppliers.
• Assess suppliers’ quality systems for compliance with Good Manufacturing Practices and ISO 13485 where applicable.
• Audit suppliers focusing on raw material sourcing, manufacturing processes, and change control mechanisms.
• Verify that suppliers provide Certificates of Analysis (CoA) and Certificates of Compliance to applicable pharmacopeial or regulatory standards.

Material Characterization

• Request comprehensive extractables studies presenting the chemical identity and levels of potential compounds under various extraction conditions.
• Confirm polymer grade suitability for biopharmaceutical use, including compliance to USP Class VI or ISO 10993 for biocompatibility.
• Incorporate knowledge of the polymer’s physicochemical properties affecting extraction, such as porosity, surface area, and chemical resistance.

Supplier and material qualification should be aligned with the principles outlined in the EMA’s guideline on extractables and leachables to maintain robust documentation and scientific rigor required by regulatory authorities.

Step 2: Risk Assessment and Prioritization for Extractables and Leachables

A formal risk assessment framework is essential for defining the scope and intensity of leachables and extractables testing aligned to GMP biotechnology manufacturing. Begin by collecting all relevant data on the SUS materials, process conditions, and drug product formulation.

Parameters for Risk Categorization

• Contact type and duration: Differentiate between direct contact (e.g., product contact bags) and indirect contact components, and consider process time and storage duration.
• Process conditions: Temperature, pH, ionic strength, solvent polarity, and other parameters influencing chemical migration.
• Therapeutic dose and route of administration: Lower dose potent biologics demand stricter leachable limits.
• Material complexity: Blend of polymers or multilayer films typically carry higher risk.

Implementation of ICH Q3E Principles

Apply the risk-based methodology consistent with ICH Q3E (Impurities: Leachables in New Drug Products) to generate a tiered testing approach:

• High risk: Required to conduct full extractables and leachables profiling.
• Medium risk: Targeted extractables analysis and leachables monitoring.
• Low risk: Documentation of justification with limited testing, focusing on supplier data and historical knowledge.

This step ensures that resources are focused on components and scenarios posing the greatest risk to product purity and safety, facilitating GMP compliance while optimizing operational efficiency.

Step 3: Conducting Extractables Studies Under Controlled Laboratory Conditions

Extractables studies provide the basis for predicting potential leachables in single-use systems. These studies require standardized, replicable procedures with detailed documentation.

Selection of Extraction Solvents and Conditions

• Use solvents representing the extremes of the intended process fluid polarity such as water, ethanol/water mixtures, and aggressive organic solvents like dichloromethane.
• Implement accelerated conditions, for example, elevated temperatures and extended contact times, simulating worst-case process scenarios.
• Follow protocols outlined in USP General Chapters, EMA, and PIC/S guidelines, ensuring regulatory acceptance.

Analytical Techniques

Employ an array of orthogonal analytical techniques to maximize detection and identification of extractables compounds:

• Gas Chromatography–Mass Spectrometry (GC-MS) for volatile/semi-volatile organics.
• Liquid Chromatography–Mass Spectrometry (LC-MS) for semi-volatile and non-volatile organics.
• Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for elemental impurities.
• Headspace GC for residual solvents and volatile compounds.
• Fourier Transform Infrared Spectroscopy (FTIR) and nuclear magnetic resonance (NMR) as supporting methods for structural elucidation.

Data Interpretation and Reporting

Report all extractables with chemical identification, concentration levels (ppm or µg/mL), and relevant physicochemical properties. Document clear justifications for analytically undetected compounds or method limitations. This comprehensive data serves as the input for toxicological and risk assessments.

Step 4: Leachables Testing During Process Simulation and Stability Studies

Leachables testing confirms actual migration into the drug substance or product under real or simulated manufacturing and storage conditions. This step is vital to verify predictions generated through extractables testing and risk assessment.

Design of Process Simulation Studies

• Perform matrix simulations using actual process fluids or appropriate surrogates under process-operating temperatures, pressures, and durations.
• Conduct testing both at the point of manufacture and at end-of-shelf-life conditions defined by product stability protocols.
• Apply standard sampling plans with adequate replicates to capture variability.

Stability Sample Analysis

Analyze stability batches at predetermined intervals to monitor leachable profiles over time, considering interactions between the drug product and container system. Use validated methods traceable to those employed in extractables studies.

Analytical Method Validation

Ensure all analytical methods employed for leachables detection are validated for sensitivity, specificity, and accuracy in biologic matrices per ICH Q2(R1) guidelines. Limits of detection and quantitation must be compatible with toxicological safety thresholds.

Step 5: Toxicological Risk Assessment and Establishment of Acceptable Limits

Integrate chemical data from extractables and leachables studies with toxicological assessments to determine safe exposure limits, ensuring patient protection in compliance with GMP.

Toxicological Data Sources

• Utilize publicly available toxicological databases such as Thresholds of Toxicological Concern (TTC) frameworks.
• Consult relevant ICH guidance, including ICH M7 for mutagenic impurities.
• Review supplier toxicological data, industry publications, and pharmacopoeia references.

Threshold Setting

• Establish Permitted Daily Exposure (PDE) or Thresholds of Toxicological Concern (TTC) levels for individual leachables.
• Apply conservative safety factors suitable for chronic or parenteral exposure routes as applicable.
• Define acceptance criteria for total leachables burden and individual compounds.

This toxicological risk assessment should be documented in a comprehensive report forming a critical part of the drug master file (DMF) or regulatory submissions.

Step 6: Establishing Ongoing Control Strategies and Change Management

The final step involves implementing long-term control measures to maintain GMP compliance and ensure product quality over the lifecycle.

Control Strategy Components

• Specification of single-use materials incorporating leachables and extractables profiles into supplier contracts and quality agreements.
• Routine incoming material testing via targeted extractables monitoring or spot checks.
• In-process testing plans for leachables monitoring at critical manufacturing stages.
• Periodic review of the leachables risk assessment tied to stability and post-approval changes.

Change Control and Documentation

Implement a strict change management program encompassing supplier changes, material reformulations, process modifications, and packaging alterations. Each change must be evaluated for potential impact on leachables characteristics with documentation updated accordingly. This approach reflects the expectations of regulatory agencies like the MHRA and FDA to sustain compliance during product lifecycle management.

Conclusion: Ensuring Safe and Compliant Use of Single-Use Systems in Biotechnology Manufacturing

Managing leachables and extractables controls in GMP biotechnology single-use systems is a multidisciplinary endeavor demanding scientific diligence and regulatory awareness. Adhering to the outlined step-by-step tutorial—from supplier qualification through toxicological risk assessment to ongoing quality control—ensures that biologic drug products meet the highest safety and quality standards required by FDA, EMA, MHRA, and ICH regulators.

Continuous improvement, rigorous documentation, and proactive risk management form the cornerstone of successful leachable control programs within single-use manufacturing environments, ultimately safeguarding patient health on a global scale.